Royalty Report: Drugs, Disease, Therapeutic – Collection: 253916


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 6


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6

Primary Industries

  • Drugs
  • Disease
  • Therapeutic
  • Pharmaceuticals
  • Viral Infection
  • Antibiotic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 253916

License Grant
Licensor grants to the Licensee of England an exclusive license and sublicense, with the right to sublicense, under the Licensed Technology and Licensors interest in any Joint Patents solely to register,  including conducting such clinical trials as may be required to support and maintain such registrations,  Products with a Regulatory Authority, and to Develop, use, sell, offer for sale, and import Products, in each case of clauses,  in the Field in the Territory during the Term.
License Property
Licensor is developing fidaxomicin for the treatment of Clostridium difficile infection and owns or controls certain patents, know-how and other intellectual property relating to fidaxomicin.

The paternts are for 18-Membered Macrocycles And Analogs Thereof; Treatment of Diseases Associated With the Use of Antibiotics; Polymorphic Crystalline Forms Of Tiacumicin B; Compositions of Stable Tiacumicins;  Method of Treating Clostridium Difficile-Associated DIARRHEA; Treatment Of Diseases Associated With The Use Of Antibiotics;  Tiacumicin Production; and, Treatment of CDI patients with concomitant antibiotics, recurrence , and, virulent strains.

CDI shall mean Clostridium difficile infection in humans.

Clostridium difficile infection (CDI or C-dif) is a symptomatic infection due to the spore-forming bacterium, Clostridium difficile.  Symptoms include watery diarrhea, fever, nausea, and abdominal pain.[1] It makes up about 20% of cases of antibiotic-associated diarrhea.

Field of Use
Field shall mean the diagnosis, prevention and treatment of any disease or condition in humans, including CDI.

IPSCIO Record ID: 279361

License Grant
Licensor, an individual, hereby grants to Licensee an exclusive, royalty-bearing worldwide license (including the right to grant sublicenses as set forth) under the Licensed IP Rights to conduct research and to develop, make, use, offer for sale, sell and import Products for use in the Field. Licensor retains the right to practice the Licensed IP Rights for his non-commercial research purposes related to the grant entitled 'Colonization for the Prevention of Clostridium difficile Disease, Department of Veterans Affairs Merit Review, 4/1/2004-3/3 l/2009 (December 2003)', and any future VA or National Institutes of Health research grants approved in accordance with the terms of the Consulting Agreement between the parties of even date herewith. Licensor retains all rights to the Licensed IP Rights outside of the Field.
License Property
Licensed Patent Rights means
US Patent No. 6,635,260 – Methods and compositions for prevention and treatment of Clostridium difficile-associated diseases

NTCD means that certain bacterium referred to as Non-Toxigenic Clostridium difficile.

Materials means A sample of each NTCD restriction endonuclease analysis (REA) type from REA groups M, T, C, P, S, and AP, which will specifically include types M3, M13, M23, and T7. All types will be provided in duplicate, one specimen in duplicate, one specimen in chopped meat broth and the second frozen at minus 70 degrees C in glycerol.

Field of Use
Field means the use of NTCD for the detection, prevention and/or treatment of CDAD.  CDAD means Clostridium difficile-Associated Disease.
Clostridium difficile, also known as C. difficile or C. diff, is bacteria that can infect the bowel and cause diarrhoea. The infection most commonly affects people who have recently been treated with antibiotics.

IPSCIO Record ID: 237266

License Grant
The Italian Licensor grants an exclusive, even as to Licensor, license under the Licensors Patents to make, have made, use, import, offer, sell, offer for sale and have sold Licensed Products in the Field and in the Territory.

Licensor grants a nonexclusive license to use Licensor Know-how within the Territory for any purpose consistent with the rights and obligations contained in this Agreement.

License Property
The patents and know-how are for the Licensed Compound known as Ramoplanin.

Ramoplanin is a glycolipodepsipeptide antibiotic drug derived from strain ATCC 33076 of Actinoplanes.

Licensor is a pharmaceutical company interested in the identification and development of naturally produced compounds for the treatment of infectious diseases, and the commercialization of products based upon such compounds.

Licensor discovered and is developing a proprietary compound, Ramoplanin, and is currently conducting clinical trials in the U.S. of an oral formulation of Ramoplanin for the prevention of infectious diseases in patients carrying Vancomycin-resistant Enterococci ('VRE') and at risk of infection following chemotherapy or transplantation, with a view to registering a new pharmaceutical product for worldwide marketing under its trademark(s) and trade name(s).

Ramoplanin is in a Phase III clinical trial for the prevention of bloodstream infections caused by vancomycin-resistant enterococci, also known as VRE, and a Phase II clinical trial to assess the safety and efficacy of Ramoplanin to treat Clostridium difficile-associated diarrhea (CDAD).

Field of Use
Field means the treatment or prevention of any human disease.

If approved, Ramoplanin would be the first available antibiotic to prevent VRE bloodstream infections.

IPSCIO Record ID: 121

License Grant
Licensor hereby grants to Licensee a royalty-bearing, exclusive right and License in the territory, with no right to subLicense except with Licensor’s prior written approval, which approval shall not be unreasonably withheld, delayed or conditioned, under all of Licensor’s rights and interests in and to the Studies and Data, including without limitation, patents, copyrights, database rights, and any other intellectual property rights it may have in the Studies and Data, for all purposes.
License Property
The companies are parties to the Agreement, pursuant to which Licensor granted a License to certain clinical studies and data related to Licensor’s proprietary product, tolevamer. Tolevamer is a toxin binding polymer that was investigated by the Licensor for the treatment of Clostridium difficile associated diarrhea. Clostridium difficile is a species of Gram-positive spore-forming bacterium that is best known for causing antibiotic-associated diarrhea (AAD).

IPSCIO Record ID: 28765

License Grant
The companies are parties to the Agreement, pursuant to which Licensor granted a License to certain clinical studies and data related to Licensor’s proprietary product, tolevamer.  The companies now wish to amend certain provisions of the Agreement to allow Licensor to receive a royalty in the event that Licensee, or its distributor, launches an authorized generic version of the Product.
License Property
Tolevamer is a toxin binding polymer that was investigated by the Licensor for the treatment of Clostridium difficile associated diarrhea.

Clostridium difficile is a species of Gram-positive spore-forming bacterium that is best known for causing antibiotic-associated diarrhea (AAD). While it can be a minor normal component of colonic flora, the bacterium is thought to cause disease when competing bacteria in the gut have been wiped out by antibiotic treatment.

Field of Use
Tolevamer is used for the treatment of Clostridium difficile associated diarrhea.

IPSCIO Record ID: 273458

License Grant
Licensor hereby sells, transfers, and assigns to Licensee the following rights, free and clear of any liens, charges, claims, encumbrances or restrictions whatsoever (Assigned Property).

Licensor hereby grants to Licensee a worldwide, irrevocable, royalty-free, non-exclusive license, with the right to sublicense under the Licensor Licensed Know-how and Materials, to manufacture, Develop and Commercialize Bulk Compound, Compound, and Products; provided, however, that in the event that Licensor is required to pay any fees associated with Licensee’s use of any Licensor Licensed Know-how and Materials on or following the Effective Date, Licensor will notify Licensee of such fees and if Licensee agrees in writing to obtain such license, Licensor and Licensee will negotiate in good faith to determine the amount of royalty or other payment due to Licensor in consideration for the license granted.

License Property
Licensor is a biopharmaceutical company that discovers, develops and manufactures medicines for hospital-based infectious diseases.  Licensor discovered and partly developed a proprietary compound named Ramoplanin.

Compound means the compound known as Ramoplanin, as described in IND Nos. 56,341 and 66,175.  Ramoplanin is for the treatment or prevention of any human disease

The Assigned Property includes but not limited to the Assigned Patents, Assigned Know-how, Global Trademarks and Global Tradenames.

Patents include
US Application #08/993,729 (Grant #5925550) – Method for selectively increasing the ratio of single major components of antibiotic A/16686 complex.
US Application #08/444,808 (Grant #5539087) – Antibiotic A/16686 recovery process.
US Application #09/744247 (Grant #6720305B1) – Injectable formulations containing ramoplanin.

Global Trademarks and Global Tradenames include Aridro, Giraxa, Eridax, Kevrak, Nibaxa, Qrozon, Zarvic.

Field of Use
Ramoplanin is currently in development for the potential treatment of Clostridium difficile-associated disease (CDAD).

C. difficile is a spore-forming bacterium known to cause diarrhea and colitis. In the past, C. difficile-associated disease has been mainly a concern in patients who have had recent antibiotic therapy and/or are hospitalized.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.